Compare · Health Care
AbbVie vs. Eli Lilly: how they make money
The same facts for both companies, in the same order, from each company's own page and filings. It is not a ranking.
How they differ
In FY2025, Eli Lilly's revenue of $65.2B was about 1.1 times AbbVie's $61.2B (Cityfort calculation: one divided by the other).
AbbVie's largest segment is Immunology, 49.7% of revenue in FY2025; Eli Lilly's largest segment is Cardiometabolic health, 74.0% of revenue in FY2025.
United States brought in 76.2% of AbbVie's revenue in FY2025; United States brought in 66.7% of Eli Lilly's revenue in FY2025.
AbbVie's largest payer group is Customers in the US, 76.2% of revenue (FY2025); Eli Lilly's largest payer group is Customers in the US, 66.7% of revenue (FY2025).
AbbVie's page lists Eli Lilly among its competitors; Eli Lilly's page does not list AbbVie.
Each company in 5 points
AbbVie
1 · What it sells
AbbVie sells prescription medicines, and two immunology drugs, Skyrizi and Rinvoq, brought in $25.9 billion of its $61.2 billion FY2025 revenue.
Sources and detail on the AbbVie page2 · Who pays it
AbbVie reports no revenue by final payer and three US wholesalers handled substantially all its US drug sales; by location, the US paid 76.2% of FY2025 revenue and other countries 23.8%.
Sources and detail on the AbbVie page3 · What it keeps from $100
Of every $100 of FY2025 revenue, AbbVie kept $6.9 as net income after $8.2 of bought research and $9.2 of other expenses, mostly a non-cash contingent-consideration charge, while operating earnings were $24.6.
Sources and detail on the AbbVie page4 · Where the operating profit comes from
AbbVie reports one business segment and no profit by therapeutic area; immunology brought in $30.4 billion, or 49.7% of FY2025 revenue, and operating earnings were $15.1 billion.
Sources and detail on the AbbVie page5 · The one thing to watch
Skyrizi and Rinvoq were 48.7% of AbbVie's Q3 FY2026 revenue, and their basic US patents are expected to expire in 2033.
Sources and detail on the AbbVie page
Eli Lilly
1 · What it sells
Eli Lilly sells medicines in about 90 countries, and two brands, Mounjaro and Zepbound, were 56% of its $65.2 billion of FY2025 revenue.
Sources and detail on the Eli Lilly page2 · Who pays it
Lilly does not report revenue by final payer and three US wholesalers each bought 16 to 24 percent; by location, in FY2025 the US paid 66.7% of revenue, Europe 17.7%, Japan 3.3%, China 3.0% and the rest of the world 9.3%.
Sources and detail on the Eli Lilly page3 · What it keeps from $100
Of every $100 of FY2025 revenue, Lilly kept $31.7 as net income, after $0.9 of net non-operating costs and $4.5 of acquired research, a deal cost that reached $17.1 in Q3 FY2026; operating income, stated in its earnings release, was $40.4.
Sources and detail on the Eli Lilly page4 · Where the operating profit comes from
Lilly reports one segment and no profit by product, so its $26.3 billion of FY2025 operating income has no official split, though cardiometabolic medicines brought in 74.0% of revenue.
Sources and detail on the Eli Lilly page5 · The one thing to watch
In Q3 FY2026 higher volume added 53% to Lilly's revenue while lower prices took off 15%, with price down 7% in the US and 29% outside it.
Sources and detail on the Eli Lilly page
Where each $100 went
Each company's own receipt for its latest full fiscal year, with matching lines in the same order where both have them.
AbbVie
Where $100 went · FY2025
| Research and development | $14.9 |
|---|---|
| Research bought from others (acquired IPR&D) | $8.2 |
| Cost of products sold | $29.8 |
| Selling, general and admin | $22.9 |
| Other expenses (mostly contingent consideration) | $9.2 |
| Interest | $4.3 |
| Income tax | $3.9 |
| Kept as net income | $6.9 |
| Total | $100 |
Cityfort calculation from the FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $61.2 billion × 100. Other expenses are other expense ($5.8 billion, which includes a $6.5 billion contingent-consideration charge offset by other items) plus a small currency loss, minus $241 million of other operating income. Tax includes $7 million for noncontrolling interests.
Eli Lilly
Where $100 went · FY2025
| Research and development | $20.5 |
|---|---|
| Research bought from others (acquired IPR&D) | $4.5 |
| Cost of making medicines | $17.0 |
| Marketing, selling and admin | $17.0 |
| Special charges and net other costs | $1.6 |
| Income tax | $7.8 |
| Kept as net income | $31.7 |
| Total | $100 |
Cityfort calculation from FY2025 10-K. Of every $100 of revenue in FY2025: each line = line ÷ $65.2 billion × 100. Net other items were a cost, so no other income is added. Rounded lines add to $100.1.
Line items differ because each company groups its costs its own way in its filings. Only on AbbVie's receipt: Cost of products sold; Selling, general and admin; Other expenses (mostly contingent consideration); Interest. Only on Eli Lilly's receipt: Cost of making medicines; Marketing, selling and admin; Special charges and net other costs.
Revenue, net income and free cash flow
Up to five fiscal years for each company, drawn on one shared scale per measure. Amounts in US$ as reported (GAAP).
Revenue
AbbVie
Eli Lilly
See the numbers
Net income
AbbVie
Eli Lilly
See the numbers
Free cash flow
AbbVie
Eli Lilly
See the numbers
Growth and net margin, FY2021 to FY2025
Worked out over the years both pages cover, so the two growth figures use the same span. Net margin is net income as a share of revenue, as on each page.
AbbVie
- Revenue, per year
- +2.1%
- Net income, per year
- −22.2%
Eli Lilly
- Revenue, per year
- +23.2%
- Net income, per year
- +38.7%
Cityfort calculation: compound growth per year from FY2021 to FY2025 (4 years), from each page's yearly numbers, as reported.
Net margin by year
Latest quarter, against the same quarter a year earlier
Each page's latest quarter as reported; the change is a Cityfort calculation.
AbbVie
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $17.4B | $15.8B | +10.3% |
| Net income | $4.2B | $186M | +2,167.7% |
Eli Lilly
Q3 FY2026, the quarter to Sep 30, 2026, against Q3 FY2025
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $24.4B | $17.6B | +38.6% |
| Net income | $6.5B | $5.6B | +15.6% |
Sources: AbbVie S11, S25, S10, S1, S4, S9, S6, S8, S5, S7 · Eli Lilly S16, S9, S15, S1, S14, S8, S13, S7, S12, S6
Who pays each company
AbbVie
- Customers in the US · 76.2% of revenue76.2% of FY2025 revenue ($46.6 billion). Three wholesalers handled substantially all US drug sales. Shares here are by location, because AbbVie does not report revenue by final payer.
- Customers outside the US · 23.8% of revenue23.8% of FY2025 revenue ($14.6 billion), sold mainly to wholesalers and through distributors.
Eli Lilly
- Customers in the US · 66.7% of revenue66.7% of FY2025 revenue ($43.5 billion). Most products reach pharmacies, doctors and hospitals through wholesalers. Benefit managers, insurers, employers and government programs negotiate rebates. Shares here are by location, because Lilly does not report revenue by final payer.
- Customers in Europe · 17.7% of revenue17.7% of FY2025 revenue ($11.6 billion).
- Customers in Japan · 3.3% of revenue3.3% of FY2025 revenue ($2.1 billion).
- Customers in China · 3.0% of revenue3.0% of FY2025 revenue ($2.0 billion).
- Customers in the rest of the world · 9.3% of revenue9.3% of FY2025 revenue ($6.1 billion).
Revenue by segment
AbbVie
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Immunology | $30.4B | 49.7% |
| Neuroscience | $10.8B | 17.6% |
| Oncology | $6.7B | 10.9% |
| Aesthetics | $4.9B | 7.9% |
| Other key products | $3.7B | 6.1% |
| Eye care | $2.1B | 3.4% |
| All other | $2.6B | 4.3% |
Eli Lilly
FY2025
| Segment | Revenue | Share |
|---|---|---|
| Cardiometabolic health | $48.2B | 74.0% |
| Oncology | $9.4B | 14.4% |
| Immunology | $5.2B | 8.1% |
| Neuroscience | $1.4B | 2.1% |
| Other | $943M | 1.4% |
Where the revenue comes from
Revenue by region, as each company splits it, with the period.
AbbVie
FY2025
- United States76.2%
- Outside the US23.8%
Eli Lilly
FY2025
- United States66.7%
- Europe17.7%
- Rest of world9.3%
- Japan3.3%
- China3.0%
Debt and cash
AbbVie
- Debt
- $80.9B
- Cash and investments
- $10.8B
On Sep 30, 2026.
At Sep 30, 2026 AbbVie's debt exceeded its cash by $70.1 billion, up from $62.3 billion at Dec 31, 2025. That is about 2.4 times EBITDA over the last four quarters (Cityfort calculation from the Q3 FY2026 10-Q and the Q4 FY2025 to Q3 FY2026 earnings releases).
Eli Lilly
- Debt
- $49.5B
- Cash and investments
- $4.9B
On Sep 30, 2026.
At Sep 30, 2026 Lilly's debt exceeded its cash by $44.6 billion, up from $35.2 billion at Dec 31, 2025. That is about 1.2 times EBITDA over the last four quarters.
Sources: AbbVie S4, S1, S2, S3, S20, S21, S7, S8, S9, S10 · Eli Lilly S6, S1, S25, S12, S13, S14, S15
Who owns each company
AbbVie
- One class of shares.
- Officers and directors as a group: 0.1% of shares (as of Mar 6, 2026).
- BlackRock, Inc.: 8.1% (as of Jan 25, 2024).
- Vanguard Capital Management: 7.5% (as of Apr 29, 2026).
- The Vanguard Group: 0.0% (as of Mar 26, 2026).
Eli Lilly
- One class of shares.
- Officers and directors as a group: 0.1% of shares (as of Feb 25, 2026).
- Lilly Endowment Inc.: 9.6% (as of Oct 19, 2026).
- BlackRock, Inc.: 6.8% (as of Jan 29, 2024).
- Vanguard Capital Management: 6.5% (as of May 1, 2026).
- 2 more holders on the Eli Lilly page.
Sources: AbbVie S15, S4, S16, S17, S26 · Eli Lilly S20, S1, S6, S21, S22, S23
What protects each business
What each page lists as protecting the business from competitors, each with its written reason. These describe business traits, not the share.
AbbVie
- Patents on the main drugs
Basic US patents on Skyrizi and Rinvoq are expected to expire in 2033. After 2025 settlements, AbbVie expects no generic Rinvoq tablets in the US before April 2037.
- Gross profit per $100
AbbVie kept $70.2 of gross profit per $100 of revenue in FY2025, against $69.0 in FY2021.
- Research spending
AbbVie spent $9.1 billion on research and development in FY2025, 14.9% of revenue, plus $5.0 billion on research bought from others.
- Range of products
Skyrizi and Rinvoq were 42.3% of FY2025 revenue and 48.7% in Q3 FY2026. Neuroscience brought in $10.8 billion, oncology $6.7 billion and aesthetics $4.9 billion in FY2025.
- Pricing power
Medicare price setting covers Imbruvica from 2026, Vraylar and Linzess from 2027 and Botox from 2028. Humira fell 49% in FY2025, which AbbVie ties mainly to biosimilar competition.
Eli Lilly
- Patents on the main medicines
The US compound patent on tirzepatide has an estimated expiry of 2036, but generic filers notified Lilly in July 2026 that they seek approval before some or all listed patents expire.
- Research spending
Lilly spent $13.3 billion on research and development in FY2025, 20.5% of revenue, plus $2.9 billion on acquired research.
- Manufacturing build-out
Purchases of property and equipment reached $7.8 billion in FY2025, up from $1.3 billion in FY2021. Lilly also depends on China-based suppliers.
- Pricing power
Lower prices cut revenue by 6% in FY2025 and by 14% in the first nine months of 2026, while volume rose.
Where growth could come from
Each page's growth drivers. The status compares progress with what the company itself said it would do; it is not a view on the share.
AbbVie
- Skyrizi · Working: on track against what the company said$5.8B in Q3 FY2026, up from $4.7B
- Rinvoq · Working: on track against what the company said$2.7B in Q3 FY2026, up from $2.2B
- Neuroscience · Working: on track against what the company said$3.4B in Q3 FY2026, up from $2.8B
- Oncology · Mixed: partly on track$1.7B in Q3 FY2026, flat with a year earlier
- Aesthetics · Mixed: partly on track$1.18B in Q3 FY2026, down from $1.19B
- Apogee Therapeutics · New: recently announced$10.6B consideration, closed Sep 3, 2026
Eli Lilly
- Mounjaro · Working: on track against what the company saidUp 65% in Q3 FY2026
- Zepbound · Working: on track against what the company saidUp 49% in Q3 FY2026
- Foundayo · New: recently announced$184 million in Q3 FY2026
- Outside the US · Mixed: partly on trackVolume +76%, price -29%
- Retatrutide · Early: too early to judgeUS filing planned Q1 2027
- Bought-in programs · New: recently announced$18.2 billion in nine months
Sources: AbbVie S7, S1, S18, S19, S4, S21 · Eli Lilly S12, S6, S13
Dividends, buybacks, auditor and credit rating
Dividends per share and buybacks for up to five years, the independent auditor and the latest credit rating, as each page records them.
AbbVie
- Dividends per shareFY2023: $5.99 (216.7% of profit) · FY2024: $6.29 (257.7% of profit) · FY2025: $6.65 (275.8% of profit)
- Buybacks
- Dec 31, 2023: Bought 10 million of its own shares for $1.6 billion in 2023. ($1.6B)
- Dec 31, 2024: Bought 7 million shares for $1.3 billion in 2024. ($1.3B)
- Dec 31, 2025: Bought 3 million shares for $606 million in 2025. ($606M)
- Sep 30, 2026: Bought 5 million shares for $1.1 billion in the first nine months of 2026; about $1.8 billion of authorization remained at Sep 30, 2026. ($1.1B)
- AuditorErnst & Young LLP, since 2013
- Credit ratingMoody's and S&P, as stated in AbbVie's 10-Q: A2 (Moody's) and A- (S&P), outlook Stable (Moody's), positive (S&P) (Nov 3, 2026)
Eli Lilly
- Dividends per shareFY2021: $3.40 (55.3% of profit) · FY2022: $3.92 (56.6% of profit) · FY2023: $4.52 (77.7% of profit) · FY2024: $5.20 (44.2% of profit) · FY2025: $6.00 (26.1% of profit)
- Buybacks
- Dec 31, 2025: Bought $4.1 billion of its own shares during FY2025, up from $2.5 billion in FY2024. ($4.1B)
- Sep 30, 2026: Bought $4.3 billion of its own shares in the first nine months of 2026, leaving $6.6 billion on its $15.0 billion program. ($4.3B)
- AuditorErnst & Young LLP, since 1940
- Credit ratingNot checked for this page.
Risks only one page tracks
Risks whose type the other company's page does not list. Both pages track risks of these types: customer or supplier concentration, competition, pricing, debt, execution, legal cases. Every risk is on each company's page.
AbbVie
- Charges that rise with Skyrizi forecasts (other)AbbVie owes future payments mainly tied to Skyrizi sales, valued at $27.3 billion at Sep 30, 2026. Higher sales estimates raise this value, and the increase is a non-cash charge: $6.5 billion in FY2025.
Eli Lilly
Every risk type on the Eli Lilly page also appears on the other page.
Key facts
- How does AbbVie make money compared with Eli Lilly?
- AbbVie's revenue by segment in FY2025: Immunology 49.7%, Neuroscience 17.6%, Oncology 10.9%, Aesthetics 7.9%, Other key products 6.1%, and 2 more. Eli Lilly's revenue by segment in FY2025: Cardiometabolic health 74.0%, Oncology 14.4%, Immunology 8.1%, Neuroscience 2.1%, Other 1.4%.
- Which is bigger by revenue, AbbVie or Eli Lilly?
- AbbVie reported $61.2B of revenue in FY2025, and Eli Lilly reported $65.2B in FY2025.
- How much net income did AbbVie and Eli Lilly report?
- AbbVie reported net income of $4.2B in FY2025, and Eli Lilly reported $20.6B in FY2025.
- How much of every $100 did AbbVie and Eli Lilly keep as net income?
- AbbVie kept $6.9 of every $100 that came in during FY2025, and Eli Lilly kept $31.7 in FY2025 (Cityfort calculation from each company's annual report).
- How much debt and cash do AbbVie and Eli Lilly have?
- AbbVie had $80.9B of debt and $10.8B of cash and investments on Sep 30, 2026. Eli Lilly had $49.5B of debt and $4.9B of cash and investments on Sep 30, 2026.
- When do AbbVie's and Eli Lilly's fiscal years end?
- AbbVie: December 31. Eli Lilly: December 31.
Sources: AbbVie S2, S1, S10, S4, S3, S20, S21, S7, S8, S9 · Eli Lilly S3, S1, S19, S15, S6, S25, S12, S13, S14
Built from each company's page. AbbVie updated Nov 6, 2026; Eli Lilly updated Nov 1, 2026.
Sources
AbbVie
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), AbbVie Inc. (SEC EDGAR), Feb 20, 2026
- S2Form 10-K for fiscal year 2023, AbbVie Inc. (SEC EDGAR), Feb 20, 2024
- S3Form 10-K for fiscal year 2022, AbbVie Inc. (SEC EDGAR), Feb 17, 2023
- S4Form 10-Q for Q3 2026 (quarter ended Sep 30, 2026), AbbVie Inc. (SEC EDGAR), Nov 3, 2026
- S5Form 10-Q for Q2 2026 (quarter ended Jun 30, 2026), AbbVie Inc. (SEC EDGAR), Aug 3, 2026
- S6Form 10-Q for Q1 2026 (quarter ended Mar 31, 2026), AbbVie Inc. (SEC EDGAR), May 8, 2026
- S7Q3 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Oct 30, 2026
- S8Q2 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Jul 31, 2026
- S9Q1 2026 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Apr 29, 2026
- S10Q4 and full-year 2025 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Feb 4, 2026
- S11Q3 2025 earnings release (Form 8-K Exhibit 99.1), AbbVie Inc. (SEC EDGAR), Oct 31, 2025
- S152026 proxy statement (DEF 14A) for the May 8, 2026 annual meeting, AbbVie Inc. (SEC EDGAR), Mar 23, 2026
- S16Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 26, 2026
- S17Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), Apr 29, 2026
- S18Form 8-K (Item 7.01) filed Jun 22, 2026: agreement to acquire Apogee Therapeutics, Exhibit 99.1, AbbVie Inc. (SEC EDGAR), Jun 22, 2026
- S19Form 8-K (Item 7.01) filed Sep 3, 2026: Apogee acquisition completed, Exhibit 99.1, AbbVie Inc. (SEC EDGAR), Sep 3, 2026
- S20Form 8-K (Item 8.01) filed Mar 4, 2026: $8.0 billion senior notes offering completed, AbbVie Inc. (SEC EDGAR), Mar 4, 2026
- S21Form 8-K (Item 8.01) filed Aug 18, 2026: $10.0 billion senior notes offering completed, AbbVie Inc. (SEC EDGAR), Aug 18, 2026
- S25SEC XBRL company facts for CIK 0001551152, SEC EDGAR, Nov 6, 2026
- S26SEC EDGAR submissions index for AbbVie Inc. (CIK 0001551152), SEC EDGAR, Nov 6, 2026
- S29Bambusa Therapeutics, Inc. final prospectus filed under Rule 424(b)(4), dated Oct 29, 2026 (competition section, pp. 146 and 197-198), SEC EDGAR (filed by Bambusa Therapeutics, Inc., CIK 0002044950), Oct 30, 2026
Eli Lilly
- S1Form 10-K for fiscal year 2025 (ended Dec 31, 2025), Eli Lilly and Company (SEC EDGAR), Feb 12, 2026
- S2Form 10-K for fiscal year 2024, Eli Lilly and Company (SEC EDGAR), Feb 19, 2025
- S3Form 10-K for fiscal year 2023, Eli Lilly and Company (SEC EDGAR), Feb 21, 2024
- S4Form 10-K for fiscal year 2022, Eli Lilly and Company (SEC EDGAR), Feb 22, 2023
- S6Form 10-Q for Q3 FY2026 (ended Sep 30, 2026), Eli Lilly and Company (SEC EDGAR), Oct 29, 2026
- S7Form 10-Q for Q2 FY2026 (ended Jun 30, 2026), Eli Lilly and Company (SEC EDGAR), Aug 5, 2026
- S8Form 10-Q for Q1 FY2026 (ended Mar 31, 2026), Eli Lilly and Company (SEC EDGAR), Apr 30, 2026
- S9Form 10-Q for Q3 FY2025 (ended Sep 30, 2025), Eli Lilly and Company (SEC EDGAR), Oct 30, 2025
- S12Earnings release, Q3 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Oct 29, 2026
- S13Earnings release, Q2 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Aug 5, 2026
- S14Earnings release, Q1 FY2026 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Apr 30, 2026
- S15Earnings release, Q4 FY2025 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Feb 4, 2026
- S16Earnings release, Q3 FY2025 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Oct 30, 2025
- S19Earnings release, Q4 FY2024 (8-K Ex. 99.1), Eli Lilly and Company (SEC EDGAR), Feb 6, 2025
- S20Proxy statement (DEF 14A) for the 2026 annual meeting, Eli Lilly and Company (SEC EDGAR), Mar 20, 2026
- S21Schedule 13G/A, Lilly Endowment Inc., event Sep 30, 2026, Lilly Endowment Inc. (SEC EDGAR), Oct 19, 2026
- S22Schedule 13G, Vanguard Capital Management, event Mar 31, 2026, Vanguard Capital Management (SEC EDGAR), May 1, 2026
- S23Schedule 13G/A, The Vanguard Group, event Mar 13, 2026, The Vanguard Group (SEC EDGAR), Mar 26, 2026
- S25Form 8-K Item 8.01, senior notes offering completed May 20, 2026, Eli Lilly and Company (SEC EDGAR), May 20, 2026
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.